Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Prehospital Cath Lab Activation in Australia Linked to Better STEMI Survival

News Daily News

Prehospital Cath Lab Activation in Australia Linked to Better STEMI Survival

July 20, 2023

Top Heart Rhythm News of 2022

News Daily News

Top Heart Rhythm News of 2022

January 05, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

News Daily News

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

July 14, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

News Daily News

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

March 25, 2022

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

March 22, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Based on Machine Learning, PRAISE Score Balances Risks in Post-ACS Care

News Daily News

Based on Machine Learning, PRAISE Score Balances Risks in Post-ACS Care

Yael L. Maxwell

January 26, 2021

Uptick in Heparin-Induced Thrombocytopenia in COVID-19 Complicates Care

News Daily News

Uptick in Heparin-Induced Thrombocytopenia in COVID-19 Complicates Care

Michael O'Riordan

October 02, 2020

Study Affirms Thrombotic Risk in COVID-19

News Daily News

Study Affirms Thrombotic Risk in COVID-19

October 01, 2020

COVID-19: TCTMD’s Daily Dispatch for September

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September

September 01, 2020

Could Statins Curb Fatal or Severe COVID-19? Some Clues

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.